The Lidara study showed SERD benefit in patients without pre-existing ESR1 mutations. Success is likely multifactorial: SERDs are more effective and better tolerated than AIs. Critically, they also prevent the most common resistance mechanism—the acquisition of ESR1 mutations—from developing in the first place, altering the disease's future trajectory.

In premenopausal patients, chemotherapy's observed benefit may be an indirect effect of inducing menopause, rather than its cell-killing properties. The ongoing OFFSET trial is testing if optimizing endocrine therapy with ovarian suppression can achieve the same risk reduction as chemotherapy, potentially avoiding chemo's side effects entirely for this group.

Ladera showed a significant benefit for geridesterant over standard endocrine therapy in early breast cancer with an efficacy signal similar to initial readouts for CDK4/6 inhibitors. Since CDK4/6 inhibitors were excluded, this creates a clinical debate: are these treatments interchangeable, sequential, or for different populations?

Citing powerful long-term data from the SOFT and TEXT trials, some oncologists are leaning away from chemotherapy for premenopausal patients with intermediate Oncotype scores (e.g., <25). They argue that the substantial, proven benefits of ovarian function suppression (OFS) may be equivalent to the chemotherapy benefit seen in trials like TAILORx.

The failure of Roche's gerodestrant when combined with a CDK4/6 inhibitor suggests these oral SERDs may not add benefit to that backbone. This contrasts with its success alone in an adjuvant setting, reframing the drugs as an "either-or" choice rather than a combination therapy in the first-line setting.

Uniquely, the EMPRIS window study in premenopausal patients showed geridestran monotherapy was more effective at suppressing proliferation than tamoxifen without adding an LHRH agonist. This challenges the standard practice of mandatory ovarian function suppression and could simplify treatment for younger women.

While the Lidera trial showed a benefit for the oral SERD giredestrant in the adjuvant setting, experts advise caution before changing practice. The trial's control arm (standard endocrine therapy) does not reflect the current standard of care for high-risk patients, which now includes CDK4/6 inhibitors, making a direct comparison difficult.

The Phase 3 Ladera study found gerodestrin not only reduced the risk of recurrence by 30% over standard endocrine therapy but also caused fewer treatment discontinuations due to side effects. This dual benefit of superior efficacy and improved tolerability represents a significant potential advancement for patients with ER-positive early breast cancer.

Unlike some endocrine therapies, oral SERDs used in premenopausal women require concurrent ovarian suppression (e.g., with a GnRH agonist). This is a critical safety measure to mitigate the risk of developing ovarian cysts, a potential side effect of using these agents without adequately suppressing ovarian function.